Literature DB >> 22351630

Obesity and adipokines: effects on sympathetic overactivity.

Michael M Smith1, Christopher T Minson.   

Abstract

Excess body weight is a major risk factor for cardiovascular disease, increasing the risk of hypertension, hyperglycaemia and dyslipidaemia, recognized as the metabolic syndrome. Adipose tissue acts as an endocrine organ by producing various signalling cytokines called adipokines (including leptin, free fatty acids, tumour necrosis factor-α, interleukin-6, C-reactive protein, angiotensinogen and adiponectin). A chronic dysregulation of certain adipokines can have deleterious effects on insulin signalling. Chronic sympathetic overactivity is also known to be present in central obesity, and recent findings demonstrate the consequence of an elevated sympathetic outflow to organs such as the heart, kidneys and blood vessels. Chronic sympathetic nervous system overactivity can also contribute to a further decline of insulin sensitivity, creating a vicious cycle that may contribute to the development of the metabolic syndrome and hypertension. The cause of this overactivity is not clear, but may be driven by certain adipokines. The purpose of this review is to summarize how obesity, notably central or visceral as observed in the metabolic syndrome, leads to adipokine expression contributing to changes in insulin sensitivity and overactivity of the sympathetic nervous system.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22351630      PMCID: PMC3573303          DOI: 10.1113/jphysiol.2011.221036

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  158 in total

Review 1.  An adipose-specific control of thermogenesis in body weight regulation.

Authors:  A G Dulloo; J Jacquet
Journal:  Int J Obes Relat Metab Disord       Date:  2001-12

2.  Plasma leptin is independently associated with the intima-media thickness of the common carotid artery.

Authors:  M Ciccone; R Vettor; N Pannacciulli; A Minenna; M Bellacicco; P Rizzon; R Giorgino; G De Pergola
Journal:  Int J Obes Relat Metab Disord       Date:  2001-06

3.  Annual medical spending attributable to obesity: payer-and service-specific estimates.

Authors:  Eric A Finkelstein; Justin G Trogdon; Joel W Cohen; William Dietz
Journal:  Health Aff (Millwood)       Date:  2009-07-27       Impact factor: 6.301

4.  Leptin interacts with heart rate but not sympathetic nerve traffic in healthy male subjects.

Authors:  K Narkiewicz; M Kato; B G Phillips; C A Pesek; I Choe; M Winnicki; P Palatini; W I Sivitz; V K Somers
Journal:  J Hypertens       Date:  2001-06       Impact factor: 4.844

5.  Prognostic relevance of pathological sympathetic activation after acute thromboembolic stroke.

Authors:  D Sander; K Winbeck; J Klingelhöfer; T Etgen; B Conrad
Journal:  Neurology       Date:  2001-09-11       Impact factor: 9.910

6.  beta-Adrenergic regulation of IL-6 release from adipose tissue: in vivo and in vitro studies.

Authors:  V Mohamed-Ali; L Flower; J Sethi; G Hotamisligil; R Gray; S E Humphries; D A York; J Pinkney
Journal:  J Clin Endocrinol Metab       Date:  2001-12       Impact factor: 5.958

7.  Presence of increased stiffness of the common carotid artery and endothelial dysfunction in severely obese children: a prospective study.

Authors:  P Tounian; Y Aggoun; B Dubern; V Varille; B Guy-Grand; D Sidi; J P Girardet; D Bonnet
Journal:  Lancet       Date:  2001-10-27       Impact factor: 79.321

8.  Leptin impairs cardiovagal baroreflex function at the level of the solitary tract nucleus.

Authors:  Amy C Arnold; Hossam A Shaltout; Patricia E Gallagher; Debra I Diz
Journal:  Hypertension       Date:  2009-09-21       Impact factor: 10.190

Review 9.  The effect of obesity on health outcomes.

Authors:  John B Dixon
Journal:  Mol Cell Endocrinol       Date:  2009-07-21       Impact factor: 4.102

10.  Non-esterified fatty acids increase arterial pressure via central sympathetic activation in humans.

Authors:  John P Florian; James A Pawelczyk
Journal:  Clin Sci (Lond)       Date:  2009-10-02       Impact factor: 6.124

View more
  69 in total

Review 1.  Sympathetic nervous system as a target for aging and obesity-related cardiovascular diseases.

Authors:  Priya Balasubramanian; Delton Hall; Madhan Subramanian
Journal:  Geroscience       Date:  2018-12-05       Impact factor: 7.713

2.  Neural control of blood flow during exercise in human metabolic syndrome.

Authors:  Jacqueline K Limberg; Barbara J Morgan; Joshua J Sebranek; Lester T Proctor; Marlowe W Eldridge; William G Schrage
Journal:  Exp Physiol       Date:  2014-03-21       Impact factor: 2.969

3.  Maslinic acid protects against obesity-induced nonalcoholic fatty liver disease in mice through regulation of the Sirt1/AMPK signaling pathway.

Authors:  Chian-Jiun Liou; Yi-Wen Dai; Chia-Ling Wang; Li-Wen Fang; Wen-Chung Huang
Journal:  FASEB J       Date:  2019-07-30       Impact factor: 5.191

4.  Comparison of EQ-5D-3L and metabolic components between patients with hyperhidrosis and the general population: a propensity score matching analysis.

Authors:  Yea-Chan Lee; Young Kyung You; Jun Hyuk Lee; Duk Hwan Moon; Sungsoo Lee; Soyoung Jeon; Hye Sun Lee; Ji-Won Lee
Journal:  Qual Life Res       Date:  2021-05-11       Impact factor: 4.147

5.  BK channel β1-subunit deficiency exacerbates vascular fibrosis and remodelling but does not promote hypertension in high-fat fed obesity in mice.

Authors:  Hui Xu; Hannah Garver; Roxanne Fernandes; Jeremiah T Phelps; Jack J Harkema; James J Galligan; Gregory D Fink
Journal:  J Hypertens       Date:  2015-08       Impact factor: 4.844

6.  Novel intracellular mediator of adiponectin secretion from adipocytes.

Authors:  Mariko Omatsu-Kanbe; Hiroshi Matsuura
Journal:  J Physiol       Date:  2014-12-01       Impact factor: 5.182

Review 7.  Microvascular perfusion heterogeneity contributes to peripheral vascular disease in metabolic syndrome.

Authors:  Jefferson C Frisbee; Adam G Goodwill; Stephanie J Frisbee; Joshua T Butcher; Fan Wu; Paul D Chantler
Journal:  J Physiol       Date:  2014-12-18       Impact factor: 5.182

Review 8.  Anti-hypertensive drug treatment of patients with and the metabolic syndrome and obesity: a review of evidence, meta-analysis, post hoc and guidelines publications.

Authors:  Jonathan G Owen; Efrain Reisin
Journal:  Curr Hypertens Rep       Date:  2015-06       Impact factor: 5.369

9.  Inhibition of ERK1/2 pathway suppresses adiponectin secretion via accelerating protein degradation by Ubiquitin-proteasome system: relevance to obesity-related adiponectin decline.

Authors:  Dongfang Gu; Zhigang Wang; Xiaobing Dou; Ximei Zhang; Songtao Li; Lyndsey Vu; Tong Yao; Zhenyuan Song
Journal:  Metabolism       Date:  2013-03-12       Impact factor: 8.694

Review 10.  Translating carotid body function into clinical medicine.

Authors:  Rodrigo Iturriaga
Journal:  J Physiol       Date:  2017-11-23       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.